Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Contineum Therapeutics Inc (CTNM)

Contineum Therapeutics Inc (CTNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 454,671
  • Shares Outstanding, K 29,183
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,260 K
  • EBIT $ -68 M
  • EBITDA $ -68 M
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.59

Options Overview Details

View History
  • Implied Volatility 148.42% (+8.31%)
  • Historical Volatility 68.06%
  • IV Percentile 7%
  • IV Rank 9.43%
  • IV High 502.36% on 06/02/25
  • IV Low 111.58% on 01/23/26
  • Expected Move (DTE 26) 1.97 (12.66%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 6
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 1.45
  • Today's Open Interest 257
  • Open Int (30-Day) 210
  • Expected Range 13.61 to 17.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.50
  • Number of Estimates 4
  • High Estimate -0.45
  • Low Estimate -0.59
  • Prior Year -0.56
  • Growth Rate Est. (year over year) +10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.63 +34.02%
on 01/21/26
16.01 -2.69%
on 02/11/26
+3.73 (+31.48%)
since 01/20/26
3-Month
8.60 +81.16%
on 01/08/26
16.01 -2.69%
on 02/11/26
+3.36 (+27.50%)
since 11/20/25
52-Week
3.35 +365.07%
on 05/29/25
16.01 -2.69%
on 02/11/26
+7.68 (+97.22%)
since 02/20/25

Most Recent Stories

More News
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 15.58 (-2.63%)
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 15.58 (-2.63%)
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 15.58 (-2.63%)
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 15.58 (-2.63%)
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 15.58 (-2.63%)
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

- PIPE-307 demonstrated an acceptable safety and tolerability profile - PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast...

CTNM : 15.58 (-2.63%)
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 ...

CTNM : 15.58 (-2.63%)
RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Contineum Therapeutics, Inc. Class A today and set a price target of $25.00. The company’s shares closed yesterday at $11.93.Elevate Your...

CTNM : 15.58 (-2.63%)
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

- PIPE-791 achieved high LPA1 brain receptor occupancy (RO) in healthy volunteers and progressive multiple sclerosis (PrMS) patients - PIPE-791 showed a safety...

CTNM : 15.58 (-2.63%)
Contineum Therapeutics to Present at September Investor Conferences

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 15.58 (-2.63%)

Business Summary

Contineum Therapeutics Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies which target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications...

See More

Key Turning Points

3rd Resistance Point 16.44
2nd Resistance Point 16.14
1st Resistance Point 15.86
Last Price 15.58
1st Support Level 15.28
2nd Support Level 14.98
3rd Support Level 14.70

See More

52-Week High 16.01
Last Price 15.58
Fibonacci 61.8% 11.17
Fibonacci 50% 9.68
Fibonacci 38.2% 8.19
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar